<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-type="olc" bill-stage="Introduced-in-Senate" dms-id="A1" public-private="public" slc-id="S1-TAM22A69-T2J-0G-SC1"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>117 S4351 IS: Enhanced Access to Affordable Medicines Act of 2022</dc:title>
<dc:publisher>U.S. Senate</dc:publisher>
<dc:date>2022-06-06</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">II</distribution-code><congress>117th CONGRESS</congress><session>2d Session</session><legis-num>S. 4351</legis-num><current-chamber>IN THE SENATE OF THE UNITED STATES</current-chamber><action><action-date date="20220606">June 6, 2022</action-date><action-desc><sponsor name-id="S401">Mr. Romney</sponsor> (for himself, <cosponsor name-id="S388">Ms. Hassan</cosponsor>, <cosponsor name-id="S402">Ms. Rosen</cosponsor>, and <cosponsor name-id="S408">Mr. Hickenlooper</cosponsor>) introduced the following bill; which was read twice and referred to the <committee-name committee-id="SSHR00">Committee on Health, Education, Labor, and Pensions</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title>To amend the Federal Food, Drug, and Cosmetic Act to clarify the conditions under which the Secretary of Health and Human Services can approve generic drug applications with labeling temporarily different than the brand name drug, and for other purposes.</official-title></form><legis-body style="OLC" display-enacting-clause="yes-display-enacting-clause" id="H5C3A700BE2364BA18C20D004CBE2BBA8"><section section-type="section-one" id="H1B07AB956C1B474B9219B9A99470A67B"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Enhanced Access to Affordable Medicines Act of 2022</short-title></quote>.</text></section><section id="H466046337AB94C42A588F48E427CB7D9"><enum>2.</enum><header>Enhancing access to affordable medicines</header><text display-inline="no-display-inline">Section 505(j)(10)(A) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(j)(10)(A)</external-xref>) is amended by striking clauses (i) through (iv) and inserting the following:</text><quoted-block style="OLC" display-inline="no-display-inline" id="H7A045EEB92924B0B8A22456435FC9B30"><clause id="H3DC3AB413DB74A3B974923225656F845" indent="up2"><enum>(i)</enum><text display-inline="yes-display-inline">a revision to the labeling of the listed drug has been approved by the Secretary within 90 days of when the application is otherwise eligible for approval under this subsection;</text></clause><clause indent="up2" id="idB2D8F1F21DAC483D99A46CCD116FD750"><enum>(ii)</enum><text display-inline="yes-display-inline">the sponsor of the application agrees to submit revised labeling for the drug that is the subject of the application not later than 60 days after approval under this subsection of the application; and </text></clause><clause indent="up2" id="idA76F76A38C414F81B7EF27F00A8EF697"><enum>(iii)</enum><text display-inline="yes-display-inline">the labeling revision described under clause (i) does not include a change to the ‘Warnings’ section of the labeling.</text></clause><after-quoted-block>.</after-quoted-block></quoted-block></section></legis-body></bill> 

